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Abstract: Traditionally, two-dimensional (2D) monolayer cell culture models have been used to study
in vitro conditions for their ease of use, simplicity and low cost. However, recently, three-dimensional
(3D) cell culture models have been heavily investigated as they provide better physiological
relevance for studying various disease behaviors, cellular activity and pharmaceutical interactions.
Typically, small-sized tumor spheroid models (100–500 µm) are used to study various biological and
physicochemical activities. Larger, millimetric spheroid models are becoming more desirable for
simulating native tumor microenvironments (TMEs). Here, we assess the use of ultra-large spheroid
models (~2000 µm) generated from scaffolds made from a nozzle-free, ultra-high resolution printer;
these models are explored for assessing chemotherapeutic responses with molecular doxorubicin
(DOX) and two analogues of Doxil® (Dox-NP® , DoxovesTM ) on MDA-MB-231 and MCF-7 breast
cancer cell lines. To provide a comparative baseline, small spheroid models (~500 µm) were
developed using a self-aggregation method of MCF-7 breast cancer cell lines, and underwent similar
drug treatments. Analysis of both large and small MCF-7 spheroids revealed that Dox-NP tends
to have the highest level of inhibition, followed by molecular doxorubicin and then Doxoves.
The experimental advantages and drawbacks of using these types of ultra-large spheroids for cancer
research are discussed.
Keywords: spheroids; nanoparticles; doxorubicin; ultra-large spheroids; chemotherapeutics; doxil;
breast cancer; triple negative breast cancer; tumor microenvironment

1. Introduction
Breast cancer, second only to cancers of the skin, is one of the most prevalent disease types
diagnosed in women. According to the latest incident data provided by the Centers for Disease
Control and Prevention (CDC), the United States alone reported 124 new cases and 20 deaths per
100,000 women in 2016 [1]. Variance in patient outcome depends on factors such as stage of diagnosis,
pre-existing conditions, and cancer subtype; the latter referring to diversity observed in patient-specific
tumor cells, where the presence of commonly targeted cell receptors varies [2]. Of most concern is
the triple-negative subtype, characteristically lacking genes for expression of estrogen receptor (ER),
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [3,4]. It is thus
understood that such variation requires correspondingly specific treatment options per patient.
Treatment of breast cancer can range from complete breast removal surgery, to less invasive
therapies like radiation, hormones, or chemotherapeutics [5,6]. The cost associated with treatment of
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Figure 1. Schematic of ultra-large scaffold showing top view and side view representations
representations [19].
[19].
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be the result of a metastatic characteristic of the MDA-MB-231 cell line. The difference in spheroid
formation observed on the small scale may have implications for generation of spheroids at a larger
scale and was further considered in the design of this experiment. It is recognized that the differences
in spheroid formation on the small scale may have implications for creating spheroids on the larger
scale; therefore, MCF-7 was chosen as the model cell line for this experiment in order to maintain
a quantifiable data set.
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Figure 3. Breast
cancer
celltaken
line
test spheroids (A) 24 h post-cell seeding and (B) 96 h
treatment
(5 μM),
at 5xaggregate
objective.
post-DOX treatment (5 µM), taken at 5x objective.
2.2. Chemotherapeutic Effects on Small Spheroid Cell Proliferation

Small MCF-7 spheroids were subjected to chemotherapeutic treatment as a comparative basis for
evaluation of the ultra-large spheroid model. Figure 4A displays an experimental set of the small spheroids
dosed with the varied concentrations of each chemotherapeutic compared to a control set.
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2.2. Chemotherapeutic Effects on Small Spheroid Cell Proliferation
Small MCF-7 spheroids were subjected to chemotherapeutic treatment as a comparative basis
for evaluation of the ultra-large spheroid model. Figure 4A displays an experimental set of the small
spheroids dosed with the varied concentrations of each chemotherapeutic compared to a control set.

Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW

5 of 17

Figure
images
of of
chemotherapeutic
response,
(B) (B)
percent
change
in area,
Figure4.4.Small
Smallspheroid
spheroid(A)
(A)Brightfield
Brightfield
images
chemotherapeutic
response,
percent
change
in
and
(C)
percent
viability.
area, and (C) percent viability.

Here, Day 0 corresponds to assembled spheroids preceding drug dosing, while Day 4 corresponds to
spheroid outcome approximately 96 h following. Spheroids at Day 0 exhibit a smooth, compact morphology
representative of the desired TME formation. The growth seen in the control group at Day 4 demonstrates
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Here, Day 0 corresponds to assembled spheroids preceding drug dosing, while Day 4
corresponds to spheroid outcome approximately 96 h following. Spheroids at Day 0 exhibit
a smooth, compact morphology representative of the desired TME formation. The growth seen
in the control group at Day 4 demonstrates unperturbed MCF-7 proliferation and is noted for sustaining
a more-complete periphery. In the dosed spheroids at Day 4, it is clear that each of the three
chemotherapeutics affected cell proliferation and peripheral cell interactions at higher concentrations
(5, 10 µM), while lower concentration doses produced less-apparent growth inhibition with respect
to the control group. At the median concentrations 0.5 and 1 µM, Figure 4A suggests Dox-NP® was
most effective at inhibiting spheroid expansion. At 5 µM, molecular DOX appeared to reduce spheroid
diameter most significantly compared to the nanoparticle variants. It is hypothesized that passive
nanoparticle drug release may have contributed to this result, as the molecular free drug is more readily
available for interaction with the tumor cells.
To assess proliferation quantitatively, spheroid area was measured using ImageJ analysis.
The change in area over the four-day culture was calculated from these measurements and are
displayed in Figure 4B. This graph represents this change as a percent of average change observed
in the control group, per concentration per drug, with error bars representing standard error. As so,
average growth of the control group (CTRL) is normalized to 0%. For all three drugs, the result shows
a trend of reduced area with respect to increased concentration. More so, treatment with Dox-NP®
produced the greatest average reduction of spheroid area at four of the six concentrations.
Supplementary quantitative assessment of cell proliferation was provided using luminescence
measurements following adenosine triphosphate (ATP) viability assay application. Resulting viability
was again measured as a percent of the control average, where control viability is normalized to 100%,
and is displayed in Figure 4C. Here, the error bars again represent standard error of each test group. The
trend observed in the dosed spheroids compliments that of the spheroid area processing, where viability
predominantly decreases with respect to increased drug concentration. Furthermore, it was noted that
nanoparticle variants performed with similar efficacy to the molecular DOX counterpart.
One-way analysis of variance (ANOVA) between the four treatment conditions at each
concentration was performed for both MCF-7 spheroid area difference (Figure 4B) and cell viability
(Figure 4C) data. For spheroid area, concentrations of 0.50 µM and greater produced statistically
significant change (p < 0.05). For cell viability, only the concentration of 0.10 µM was not statistically
significant. Corresponding p-values are listed in Table 1. Complimentary analysis using a Tukey test at
a 95% confidence interval was performed for each concentration and can be found in Supplementary
Materials section in Figures S1 and S2.
Table 1. ANOVA P-Values for small MCF-7 spheroid area difference and cell viability.
Area Difference

Cell Viability

p-Value

p-Value

0.05

0.143

0.005

0.10

0.311

0.694

0.50

0

0.006

1.00

0

0.004

5.00

0

0

10.0

0

0

Concentration [µM]

Prior to the result comparison with the ultra-large spheroids, the following observation were the
findings within the confine of the small-spheroid experiment:
i.

When examining change in area over the four-day period, the spheroid size has an inverse
relationship with increasing drug concentration for all three drugs. However, a notable
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observation is that all cancer cell spheroids would increase in size during this period of time
with or without the influence (verified by the control) of the drugs. The drugs resulted in
retardation to the cellular expansion in proportion to the drug strength; it was theorized that
the cell expansion could be attributed by either cellular growth or due to cellular disintegration.
The viability results of the experiment demonstrated that all three drugs had an inhibitive effect
against the cancer spheroids. However, the effects of the drugs did not become significantly
apparent until they reached 5 µM in concentration (see Figure 4C).

2.3. Chemotherapeutic Effects on Ultra-Large Spheroid Cell Proliferation
Similar to the above study of small spheroids (~500 µm), several experiments were conducted
on ultra-large spheroids (~2000 µm) to investigate their viability as a chemotherapeutic testing
platform based on spheroid size, ATP activity, and overall morphology. The breast cancer cell lines
used in this study were MCF-7 and MDA-MB-231. Scaffolds were generated from a nozzle-free,
ultra-high-resolution
printer, manufactured by Prellis Biologics, Inc. (Hayward,
CA, USA). For this
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW
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Figure 5. (A) EVOS Brightfield microscopic images (“raw”) and binary processed images (“processed”) using

Figure 5. (A) EVOS
Brightfield microscopic images (“raw”) and binary processed images (“processed”)
ImageJ of ultra-large (2000 μm) MCF-7 and MDA-MB-231 spheroids cultured in Prellis Biologics scaffolds
TM drug formulations (50 µ M).
(Day 0) and post(Day
3) treatment
with
DOX,MDA-MB-231
Dox-NPⓇ, and Doxoves
using ImageJ ofpreultra-large
(2000
µm)
MCF-7
and
spheroids
cultured in Prellis Biologics
Images taken at 4x objective. (Scale bar 2000 µ m). Below are graphical presentations of (B)®
MCF-7 and (C)
scaffolds pre- (Day
0)
and
post(Day
3)
treatment
with
DOX,
Dox-NP
, and DoxovesTM drug
MDA-MB-231 binary processed images shown in (A).
formulations (50 µM). Images taken at 4x objective. (Scale bar 2000 µm). Below are graphical
presentations of (B) MCF-7 and (C) MDA-MB-231 binary processed images shown in (A).
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The “raw” images presented in Figure 5A show a dark contrasting, external, circular border
which outlines the top view (see Figure 1) of the ultra-large scaffold framework, and a white outer
region representing the concocted DMEM cell media in which the spheroid scaffolds were submerged.
Within the scaffold framework, crossbars with white nodes act as auxiliary supports to maintain the
“basket-like” appearance of the scaffolds. The dark regions within the scaffold are spheroid formations
due to multi-cellular stacking and high cell density; consequently, the darker regions inside the scaffold
suggest more cell stacking as compared to lighter regions.
The “processed” images shown in Figure 5A were generated for high-contrast observation and
quantitative analysis. The optimal value for each image was chosen as a threshold limit to differentiate
between cells and the background (as black and white pixels, respectively). This selection was done
using visual analysis of raw images to identify and characterize the cells, artifacts, scaffold, cell media
interference, cellular discontinuities in scaffold and microscope light interference. The threshold
value was adjusted over a range of 256 bits to reflect the true cell population. These “processed”
images show a binary representation of spheroidal activity for greater contrast and quantification of
their corresponding raw image based on binary pixel threshold. Once again, there is a white region
(cell media) surrounding a dark circular region (scaffold) in which spheroid formation of tumor cells is
occurring. Inside this circular region, note the high-contrast dark zones indicative of cell-cell stacking
in forming tumor spheroids.
From Figure 5A, the raw image results present a progression from Day 0 (pre-treatment) to Day 3
(post-treatment). Take for example, the raw images for MCF-7 treated with Dox-NP® . The raw image
taken on Day 0 of Dox-NP® treatment shows a highly dense MCF-7 cell population indicated by the
large dark zones and sparse white zones within the scaffold region. Consequently, the raw image
taken on Day 3 of Dox-NP® treatment shows a drastic decline of dark zones indicative of minimal
MCF-7 cell density as a result of drug treatment on the tumor spheroid. Accordingly, the processed
images provide a clearer and quantifiable measure of the aforementioned raw images as graphed in
Figure 5B,C.
Consider the binary processed images for the previous raw images example of MCF-7 under
Dox-NP® treatment. The Day 0 binary processed image shows 67.2% of scaffold coverage within the
scaffold; the Day 3 binary processed image is 37.5% of scaffold coverage within the scaffold suggesting
a decrease in MCF-7 spheroid due to Dox-NP® drug treatment. The percentages were calculated by
taking the total number of black pixels (representation of cellular activity) obtained divided by the
total pixel count of the scaffold. The complete tabulation of the corresponding binary processed results
can be seen in Table 2.
Table 2. Quantification results (%) for spheroid area coverage by cells corresponding to Figure 5A
binary processed images of MCF-7 and MDA-MB-231. Results tabulated for pre- (Day 0) and post(Day 3) treatment with DOX, Dox-NP® , and DoxovesTM drug formulations.
Control

Molecular DOX

Dox-NP®

DoxovesTM

Cell Type

Data Type

Day 0

Day 3

Day 0

Day 3

Day 0

Day 3

Day 0

Day 3

MCF-7

scaffold coverage
(% area)

34.7

54.9

51.4

27.3

67.2

37.5

49.4

41.5

# black pixels

425,922

674,276

631,632

334,961

825,351

460,759

606,451

509,364

scaffold coverage
(% area)

57.6

54.4

52.2

34.6

47.2

46.8

46.2

46.5

# black pixels

707,343

668,893

640,883

424,733

580,588

575,383

568,289

571,259

MDA-MB-231

Following the imaging of samples on Day 3 post-treatment, ATP viability assay was conducted
using CellTiter-Glo® 3D Cell Viability Assay on 78 ultra-large tumor spheroids (MCF-7: 36 scaffolds,
3 controls; MDA-MB-231: 36 scaffolds, 3 controls). Figure 6 shows the luminescence readings (Intensity,
A.U.) for both MCF-7 and MDA-MB-231 triplicate samples exposed to drug concentrations of 0.05 µM,
0.5 µM, 5 µM, and 50 µM under four drug treatment groups (i.e., control, molecular DOX, DoxovesTM ,
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Dox-NP® ); here, the control group always consisted of no drug treatment. From the culmination of
experiments on ultra-large spheroids, it can be observed from Figure 6 that upon post processing,
the molecular DOX treatment group demonstrates the highest inhibition (i.e., lowest luminescence)
J. Mol.
Sci. 2020,
21,line,
x FORwhereas,
PEER REVIEW
of 17 highest
onInt.
the
MCF-7
cell
Dox-NP® treatment group shows the least inhibition 9(i.e.,
luminescence). With regards to the MDA-MB-231 cell line, the results are not as distinct among the
treatment group shows the least inhibition (i.e., highest luminescence). With regards to the MDA-MB-231
treatment groups.
cell line, the results are not as distinct among the treatment groups.

Figure
luminescence
seeded scaffolds
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Ⓡ
TM
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versus
a control.
5 µM,
and
50 µM
versus a control.

UsingFigure
Figure 6,
6, luminescence
luminescence readings
cancan
be compared
(i) within
a single
drug concentration
across
Using
readings
be compared
(i) within
a single
drug concentration
the
four
treatment
groups,
(ii)
between
the
two
cell
line
populations
for
the
same
drug
concentration
across the four treatment groups, (ii) between the two cell line populations for the same drug
exposure, andexposure,
(iii) across and
all four
concentrations
for aconcentrations
given cell line for
treatment
concentration
(iii)drug
across
all four drug
forthe
a given
cellgroups.
line forFor
the
example, with regards to (i), in Figure 6A, control and treatment groups for 0.05 µ M were tested on three
treatment groups. ⓇFor example, with regards to (i), in Figure 6A, control and treatment groups
replicates. Dox-NP treatment exhibits highest luminescence
as compared to control, molecular DOX and
for 0.05 µM
were tested on three replicates. Dox-NP® treatment exhibits highest luminescence
DoxovesTM treatment. The luminescence for treated spheroids
is generally higher than the control; to note,
as this
compared
to control, molecular DOX and DoxovesTM treatment. The luminescence for treated
should not be the case for an effective assay. Ideally, the control group should represent the highest
spheroids
is cells,
generally
higher
than the
control;
to note, this
should
not be the
case
for an did
effective
number of
and thus
the highest
arbitrary
luminescence
reading
for viability.
This
drawback
not
assay.
Ideally,
the
control
group
should
represent
the
highest
number
of
cells,
and
thus
the
highest
occur with the small spheroids, and therefore, may suggest that this may not be an effective method
for
arbitrary
readingfor
forultra-large
viability. spheroids,
This drawback
didsmall
not occur
with the
small
spheroids,
and
rapidly luminescence
assessing the viability
but only
spheroids.
Now
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with Figure
(i.e., MCF-7
0.05
µ Mnot
andbe
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µ M). for
Therapidly
control groups
for the
bothviability
cell typesfor
therefore,
may8A,E
suggest
that this
may
an effective0.05
method
assessing
Ⓡ
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readings,but
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DOX and
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treatment(ii)
groups;
Dox-NP8A,E
treatment
has
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spheroids,
only
spheroids.
Now
let usTMconsider
with Figure
(i.e., MCF-7
consistently
higher
luminescence
for
MCF-7
cell
types,
whereas
it
is
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to
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if
any
particular
0.05 µM and MDA-MB-231 0.05 µM). The control groups for both cell types have similar readings,
group is superior in the MDA-MB-231 cell type. Finally, let us take Figure 8A–D as an example
as treatment
do the molecular
DOX and DoxovesTM treatment groups; Dox-NP® treatment has consistently
for (iii), luminescence readings for MCF-7 ultra-large spheroids under the three treatment groups and a
higher luminescence for MCF-7 cell types, whereas it is difficult to claim if any particular treatment
control group at the four drug concentrations (0.05 µ M, 0.5 µ M, 5 µ M, and 50 µ M). We can observe here
group
is superior in the MDA-MB-231 cell type. Finally, let us take Figure 8A–D as an example for (iii),
that all triplicates of the MCF-7 sample follow a similar trend of luminescence readings compared to any
luminescence
readings
MCF-7
ultra-large
spheroids
three
groups andreadings
a control
Ⓡ
other treatment
group. for
Overall,
triplicates
for Dox-NP
forunder
MCF-7the
show
thetreatment
highest luminescence
group
at the four
drug concentrations
(0.05forµM,
0.5 µM,
5 µM,
and 50 µM).
We can
observe
that all
consistently
throughout
all concentrations
MCF-7
samples.
Therefore,
according
to Figure
6, ahere
standard
triplicates
of theofMCF-7
sample follow
a similar
trend
of luminescence
compared
to any
other
interpretation
the luminescence
readings
would
indicate
that Dox-NPⓇreadings
has the least
inhibitive
activity
® for MCF-7
out of thegroup.
treatments
usedtriplicates
for MCF-7 for
spheroids;
cells tend
to form
regular spheroids,
treatment
Overall,
Dox-NPMCF-7
show
the uniform
highest and
luminescence
readings
and due to throughout
these characteristics,
it may contribute
to the consistency
drug (andaccording
ATP reagent)
results. 6,
consistently
all concentrations
for MCF-7
samples. in
Therefore,
to Figure
®
Conversely,
for
MDA-MB-231
samples,
all
three
drug
treatment
groups
show
minimal
differences
in
effects,
a standard interpretation of the luminescence readings would indicate that Dox-NP has the
least
suggesting
that
due
to
the
irregularity
in
MDA-MB-231
spheroid
formation
behavior,
drug
(and
ATP
inhibitive activity out of the treatments used for MCF-7 spheroids; MCF-7 cells tend to form uniform
reagent) results consistency poses difficulty.
and regular spheroids, and due to these characteristics, it may contribute to the consistency in drug
One-way ANOVA between the four treatment conditions at each concentration was performed for
(and ATP reagent) results. Conversely, for MDA-MB-231 samples, all three drug treatment groups
both MCF-7 and MDA-MB-231 spheroid cell viability (Figure 6) data. For spheroid cell viability,
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show minimal differences in effects, suggesting that due to the irregularity in MDA-MB-231 spheroid
formation behavior, drug (and ATP reagent) results consistency poses difficulty.
One-way ANOVA between the four treatment conditions at each concentration was performed
for both MCF-7 and MDA-MB-231 spheroid cell viability (Figure 6) data. For spheroid cell viability,
concentrations of 0.50 µM, 5.00 µM and 50.0 µM for both cell lines were statistically significant (p < 0.05).
Corresponding p-values are listed in Table 3 per cell line samples. Complimentary analysis using
a Tukey test at a 95% confidence interval was performed for each concentration and cell line sample
which can be found in the Supplementary Materials section in Figure S3.
Table 3. ANOVA P-Values for ultra-large MCF-7 and MDA-MB-231 spheroid cell viability.

Concentration [µM]

0.05
0.50
5.00
50.0

MCF-7
Cell Viability

MDA-MB-231
Cell Viability

p-Value

p-Value

0.280
0.019
0.020
0.033

0.324
0.012
0.023
0.012

Figure 5A and Table 2 show cell viability approximations based on ImageJ thresholding analysis
and serve as an observation of the treatment effectivity of the drug formulations on both the MCF-7 and
MDA-MB-231. However, the graphical results obtained from ATP quantitative viability assessments
in Figure 6 present an unsatisfying narrative that does not completely align with the image-based
viability results found in Figure 5A. For example, from Figure 5A and Table 2, Dox-NP® demonstrates
a decrease in MCF-7 spheroid size from 67.2% (Day 0) to 37.5% (Day 3) due to drug treatment; however,
from Figure 6, Dox-NP® shows highest luminescence readings (i.e., high ATP activity) on MCF-7
spheroids among all treatment groups. Major factors that contribute to the shortcoming of the ATP
viability assays may be based on (1) inherent luminescent properties of drugs and nanoparticles that
reflect luminescence other than that of cell viability, and (2) impenetrability of ATP reagent to effectively
diffuse through highly dense cell spheroids.
To address factors concerning (1) the luminescent properties of the drugs and nanoparticles
and (2) impenetrability of ATP reagent as mentioned in the previous paragraph, a short series of
experiments were conducted to test the penetration of ATP reagent in 2D and 3D cell culture before
testing the drug effectivity on ultra-large spheroids. Known and similar cell concentrations were
seeded in a well and on a scaffold. ATP reagent was added to both wells containing 2D and 3D
culture. The ATP reading obtained for the 2D well was higher than that of the 3D well. Despite similar
cell seeding concentrations, the ATP results varied significantly for 3D culture compared to 2D
culture. This information substantiated and guided our rationale for mentioning the factor (2)
(i.e., impenetrability of ATP reagent) in the previous paragraph and relying more on the imaging
results in Figure 5A for a reliable conclusion. Additionally, to address factor (1) (i.e., luminescent
properties of drugs and nanoparticles) scaffolds were pre-washed using PBS buffer prior to ATP assay
in order to minimize the effects of drug on luminescence readings.
2.4. Cellular Hoechst 33,342 Fluorescence Interaction with Ultra-Large Basket Scaffold
Hoechst 33,342 stain is a widely used fluorescence cell nuclei tagging tool for live and fixed cell
culture. To demonstrate cell-to-scaffold attachment and fluorescence signal collection, Hoechst stain
was applied to a live MDA-MB-231 seeded basket shown in Figure 7. Additionally, baseline images
are included to establish differences to pre- and post-Hosechst stain application. The brightfield (BF)
images of the empty basket shows no difference between the images. However, in the blue channel,
some auto-fluorescence from the basket structure is present in the pre-stain image, which is then
noticeably quenched in the post-stain image. The live BF MDA-MB-231 seeded basket images show
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little difference between pre-stain and post-stain. There is a distinct contrast difference between the
BF cell seeded baskets and the pre-seed baskets. The high density attached cells block transmitted
light, eliciting a darker less, discernible basket structure. Here, pockets lacking cell attachment or with
lower
beREVIEW
seen as slightly brighter areas on the basket due to better light penetration.
Int. J.aMol.
Sci. cell
2020,density
21, x FORcan
PEER
11 of 17
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2.5. Spheroid Formation Analysis
2.5. Spheroid Formation Analysis
Figure 8 is a demonstration of MDA-MB-231 basket attachment and tumor spheroid formation using
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3.1. Culture Preparation and Cell Spheroid Placement
3.1. Culture Preparation and Cell Spheroid Placement
Human Caucasian breast adenocarcinoma breast cancer cell lines Michigan Cancer Foundation-7
Human Caucasian breast adenocarcinoma breast cancer cell lines Michigan Cancer Foundation-7
(MCF-7) (ATCC® HTB-22™,
Manassas, VA, USA) and MD. Anderson-Metastatic Breast-231 (MDA-MB-231)
(MCF-7)
(ATCC® HTB-22™, Manassas, VA, USA) and MD. Anderson-Metastatic Breast-231
(ATCC® HTB-26™, Manassas,
VA, USA) were used in this study for the formation of both small and ultra(MDA-MB-231) (ATCC® HTB-26™, Manassas, VA, USA) were used in this study for the formation of
large, homogeneous tumor spheroids. Small spheroids were prepared through self-assembly under the
both small and ultra-large, homogeneous tumor spheroids. Small spheroids were prepared through
following conditions. MCF-7 cells were seeded at 1000 cells per well in an ultra-low attachment 96-well
self-assembly under the following conditions. MCF-7 cells were seeded at 1000 cells per well in an
plate, each containing 100 μL of Dulbecco’s Modified Eagle Medium 1X (DMEM) (Gibco ThermoFisher
ultra-low attachment 96-well plate, each containing 100 µL of Dulbecco’s Modified Eagle Medium 1X
Scientific, Waltham, MA, USA) with 10% Fetal Bovine Serum (FBS) (ATCC® , Manassas, VA, USA). Cultures
(DMEM) (Gibco ThermoFisher Scientific, Waltham, MA, USA) with 10% Fetal Bovine Serum (FBS)
were then®incubated at 37 °C for 72 h prior to drug application. At the
end of the 72 h incubation period, a
(ATCC , Manassas, VA, USA). Cultures were then incubated at 37 ◦ C for 72 h prior to drug application.
pre-treatment imaging on the 96-well plate took place to capture the cell conditions.
At the end of the 72 h incubation period, a pre-treatment imaging on the 96-well plate took place to
With respect to the ultra-large spheroids, prior to scaffold usage, MCF-7 and MDA-MB-231 cell lines
capture the cell conditions.
were prepared using standard cell culture protocols, and maintained in cell culture media (DMEM, 10%
With respect to the ultra-large spheroids, prior to scaffold usage, MCF-7 and MDA-MB-231 cell
FBS, 1% penicillin-streptomycin with fungicide) in tissue-treated bottom T-75 culture flasks at standard
lines were prepared using standard cell culture protocols, and maintained in cell culture media (DMEM,
incubation controls (37 °C, 5% CO2). The millimetric scaffolds were originally obtained from Prellis
10% FBS, 1% penicillin-streptomycin with fungicide) in tissue-treated bottom T-75 culture flasks at
Biologics, Inc. (Hayward, CA, USA) and
prepared for seeding in 3 mm petri dishes containing DMEM cell
standard incubation controls (37 ◦ C, 5% CO2 ). The millimetric scaffolds were originally obtained
culture media; they were later washed with PBS and then coated with poly L-lysine solution to minimize
from Prellis Biologics, Inc. (Hayward, CA, USA) and prepared for seeding in 3 mm petri dishes
cell spill-out from within the scaffold. Each scaffold was seeded with approximately 2 million cells from the
containing DMEM cell culture media; they were later washed with PBS and then coated with poly
appropriate cell line and incubated at standard cell culture controls (37 °C, 5% CO2). After incubation, the
L-lysine solution to minimize cell spill-out from within the scaffold. Each scaffold was seeded with
petri dishes containing the scaffolds and cells were retrieved and inspected under an EVOS upright
approximately 2 million cells from the appropriate cell line and incubated at standard cell culture
microscope for proper
cell growth and spheroid formation over a period of five days.
controls (37 ◦ C, 5% CO2 ). After incubation, the petri dishes containing the scaffolds and cells were
and inspected
under an EVOS upright microscope for proper cell growth and spheroid
3.2.retrieved
Drug Preparation
and Administration
formation over a period of five days.
Molecular Doxorubicin (DOX) (Medkoo, Morrisville, NC, USA) was evaluated against Doxorubicin
nanoparticle variants Dox-NPⓇ (Avanti Polar Lipids, Alabaster, AL, USA) and DoxovesTM (FormuMax,
Sunnyvale, CA, USA) as chemotherapeutic agents. DOX (manufactured and received as powder form) was
initially dissolved and prepared in dimethyl sulfoxide (DMSO), with histidine and sucrose as preservatives;
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3.2. Drug Preparation and Administration
Molecular Doxorubicin (DOX) (Medkoo, Morrisville, NC, USA) was evaluated against Doxorubicin
nanoparticle variants Dox-NP® (Avanti Polar Lipids, Alabaster, AL, USA) and DoxovesTM (FormuMax,
Sunnyvale, CA, USA) as chemotherapeutic agents. DOX (manufactured and received as powder
form) was initially dissolved and prepared in dimethyl sulfoxide (DMSO), with histidine and sucrose
as preservatives; afterwards, the dissolved solution was serially diluted to its desired concentration
with cell culture media. DoxovesTM and Dox-NP® (manufactured and received as liquid form) were
initially diluted with manufacturer suggested buffers (comprised with PBS, histidine, and sucrose)
less than 24 h prior to the experiment. This was done in order to ensure the preservation of the drugs
during the transportation. They were then further diluted, on Day 0 of the experiment, to their desired
concentrations with cell culture media at the time of drug administration. The drugs were prepared
less than 24 h prior to culture administration in order to minimize drug instability and degradation.
(NOTE: Appropriate precautions were taken with safety masks and PPE, as DOX is known to cause
irritation and more severely, cardiotoxicity.)
Similar to the drug preparation for the small spheroids above, DOX (MedKoo), DoxovesTM
(FormuMax) and Dox-NP® (Avanti) formulations were obtained, prepared, and adjusted to the desired
concentrations for administration to the ultra-large spheroid samples; the drugs were prepared 24 h
prior to administration. The concentrations used for the ultra-large spheroids were 0.05 µM, 0.5 µM,
5 µM, and 50 µM for three drug formulations. The treated ultra-large spheroid samples were followed
over 72 h.
3.3. Spheroid Imaging and Drug Treatment
Small spheroid images were captured under a 10x objective lens using the Keyence Fluorescence
All-in-One Microscope (Itasca, IL, USA). Pre-treatment images (Day 0) were taken per well,
followed directly by application of 100 µL of the pre-determined concentrations of DOX, Dox-NP® ,
and DoxovesTM to their pre-assigned position. Cultures were returned to incubation at 37 ◦ C for four
days. On Day 4 (>96 h), post-treatment images were then taken under identical settings.
Ultra-large spheroid images were obtained under a 4x objective lens using an EVOS brightfield
microscope. Pre-treatment images (Day 0) were taken per petri dish, followed directly by application
of 100 µL of the pre-determined concentrations of DOX, Dox-NP® , and DoxovesTM to the respective
scaffolds as determined by the experimental design. Petri dishes containing scaffold cultures were
returned to incubation at 37 ◦ C for three days. On Day 3 (>72 h), post-treatment images were then
taken under identical settings.
3.4. ATP Viability Assay
Following post-imaging, a proliferation assay was conducted via Promega’s Celltiter-Glo®
Luminescent Cell Viability Assay (Madison, WI, USA). At 50 µM and 200 µL per well, the end culture
96-well plate was transferred onto a luminesce-compatible well plate and the viability read was
captured using the Cytation 5 Cell Imaging Reader (BioTek Instruments, Inc., Winooski, VT, USA).
The viability results were then further analyzed using GraphPad Prism 8.3.0 (San Diego, CA, USA).
Similarly, for the ultra-large spheroids, cell viability reagent was prepared according to the
CellTiter-Glo® 3D Cell Viability Assay protocol [23]. The CellTiter-Glo® 3D Reagent was thawed at
4 ◦ C overnight and equilibrated to room temperature prior to use. Samples were transferred from petri
dish to a 96-well plate with clear bottom wells and microtissues prior to viability reagent application;
the samples were suspended in culture media. After application of CellTiter-Glo® 3D Reagent, the plate
luminescence was measured by a BioTek Synergy/Neo2 (Winooski, VT, USA) plate reader and recorded.
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3.5. Size Measurement
ImageJ v1.52u (NIH, Bethesda, MD, USA) open-source software was used to measure the area
of the spheroids. Keyence microscope PNG image files were uploaded to ImageJ in their original,
identical magnification and file dimensions. The area unit of the ImageJ measurements was recorded
and calculated in “pixels” at both Day 0 and Day 4 for comparison of a change in relative size.
3.6. Image Binary Processing
The raw images of seeded ultra-large scaffolds obtained from EVOS Brightfield microscopy were
processed using ImageJ v1.52u (NIH, Bethesda, MD, USA) software. The raw true color images were
converted to grayscale to identify an optimal threshold value from the 256-bit grayscale histogram plot.
3.7. Statistical Analysis
The data for both small and ultra-large spheroid samples were statistically analyzed using Minitab
19 (Penn State Univ., PA, USA) statistical analysis software. The size measurement and cell viability
data were normalized into percent difference for all concentrations, and then assessed using Minitab
19 one-way analysis of variance and Tukey with 95% confidence interval (C.I.).
3.8. Hoechst Staining
Hoechst 33,342 (Life Technologies, Eugene, OR, USA) was diluted in cell culture medium (DMEM,
10% FBS, 1.5% Pen-Strep) to a 1 µM Hoechst concentration. Cell culture medium for the 3D cell
cultures were replaced with the Hoechst 33,342 diluted cell culture medium in a 24-well plate and
were incubated (37 ◦ C, 5% CO2 ) for 15 min before imaging.
3.9. Dark-Field 3D Imaging
A fixed MDA-MB-231 seeded scaffold was transferred to a flat imaging slide using a modified
transfer pipette. The sample was maintained in a PBS droplet during the 5-min image capture process
using BrighTex Bio-Photonic’s (BTBP) ClarityPro dark-field 3D imaging technique (San Jose, CA, USA).
Images were captured using a 360◦ illumination source rotation and all images were stitched together
using the ClarityPro specialized machine learning algorithm. BTBP’s 3D viewer software was used for
image reconstruction, digital zoom, and application of the height variation heat map. Height variation
calibration was conducted with a benchmark wafer of known length, width, and height values and
was imaged in the same conditions as the scaffold sample.
3.10. Overview
For the small spheroid experiments, three consecutive experiments were conducted to ensure
repeatability and more accurate analysis. The three experiments consisted of two sets of three drugs
at 0.05 µM, 0.5 µM, and 5 µM, along with an untreated cell line as control. The third experiment
was conducted with one set of refined range of concentrations at 0.05 µM, 0.1 µM, 0.5 µM, 1.0 µM,
and 5.0 µM.
With regard to the ultra-large spheroid study, two cell lines were prepared and seeded onto large
millimetric scaffolds for culture and incubation for five days. For each cell line, a design matrix for drug
exposure of four treatment groups (i.e., three drugs and one control group) and drug concentrations
ranging from 0.05 µM, 0.5 µM, 5 µM, and 50 µM were applied. The effect of the drug treatment groups
on the ultra-large spheroids were then comparatively analyzed against the effect of the same drugs on
conventional method of self-aggregating small spheroids.
4. Conclusions
The drug testing results from image analysis of the large spheroids have a similar trend to
those from the small spheroids. The drug formulations have the same general pattern of inhibition.
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For MCF-7 spheroids, Dox-NP® tends to have the highest level of inhibition, followed by molecular
doxorubicin and then DoxovesTM . While the similarities in trends are promising, there are some
advantages and drawbacks to using the ultra-large spheroids that should be highlighted.
The advantages are related to the time it takes to culture the spheroid, the ease with which
the cells are cultured and the confinement of cells that would otherwise spread. Many cells can
easily be clustered together into a 3D formation within 24 h. Another advantage is that spheroids
can be made from cell lines like MDA-MB-231 that do not form spheroids easily. The creation of
MDA-MB-231 ultra-large spheroids on scaffolds permitted the full realization of the 3D nature of
experiments, where the cell density could be easily observed and captured. This contrasts with the
process for creating small spheroids, where the MDA-MB-231 cells spread to create a non-spheroidal
shape. Another advantage of using the rapidly generated spheroids is that image analysis can be used
to assess therapeutic inhibition to drug exposure.
Some drawbacks typically associated with new technology are present here. For example,
the scaffolds are expensive to make. Broader adoption of the technology may result in a price reduction
in the future. Another example of a drawback is that protocols should be optimized for each cell line it
is used for. We draw attention to this because the protocols may appear simple, but changes in culture
time, cell handling and the extracellular matrix used can yield different results. Lastly, an additional
drawback was recognized by light matter interactions. It was found that the larger the spheroid created,
the more difficult it becomes for light to penetrate and provide photonic-related information that can
be obtained from fluorescence assays.
Although the use of 3D spheroids was found to be advantageous to cancer cell studies, it is
recognized that a static environment does not fully represent the factors for cellular growth of these
cancer cells. It was observed that the tumor cells grew overtime without the suppression of the drugs;
however, it remains unclear how much of the growth was stunted or enhanced as a result of static
media supplies. Additionally, the experiments done thus far only considered single cell line cultures
for the entire study; co-cultures may also provide more accurate responses to drug exposure. Thus, it is
suggested that (1) a dynamic cancer cell environment (i.e., media circulation) and (2) co-culture studies
shall further improve the model and provide more insight for future similar studies. This work serves
as a foundation for creating ultra-large spheroids that can play a significant role in cancer drug testing.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/12/
4413/s1.
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